CGON
CG Oncology, Inc.
$54.40
+1.27%
$4.8B
No data for this timeframe.
Vol
Market Cap$4.8B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders6 funds
Inst. Value$547.1M
Inst. Activity2 buys / 0 sells
Insider Activity0B / 3S
Insider Net $-$1.2M
SEC Reports7
Press Releases2
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001991792·Prev Close $53.72
Recent Activity
Jun 9, 2026
short_volume
Short Volume: CGON — 64.6% short (0.4M / 0.6M)
Short: 417,438 | Exempt: 130 | TRF Vol: 646,558 | Short Ratio: 64.6% | Off-exchange volume (dark poo
Jun 4, 2026
Insider
Liu Brian Guan-Chyun sold 9,354 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
POST LEONARD E sold 1,000 shares
Director @ $0.00 ($0.00)
Jun 4, 2026
Insider
POST LEONARD E sold 1,000 shares
Director @ $0.6000 ($600.00)
May 26, 2026
SEC
CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur
8-K — Impact 3/10
May 15, 2026
Press
CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at
Impact 6/10
May 8, 2026
SEC
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and tot
8-K — Impact 5/10
May 8, 2026
SEC
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago,
PRESS-RELEASE — Impact 5/10
Price Targets
$90.29
+59.3% upside
Strong Buy
Current $56.67
Low $80.00
Median $88.50
High $108.00
14 analysts
$80.00
$108.00
Analyst Ratings
5Strong Buy
15Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | Wolfe Research | INITIATE | Peer Perform |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 14, 2026 | Truist Securities | REITERATE | Buy → Buy |
| May 11, 2026 | JP Morgan | MAINTAIN | Overweight → Overweight |
| May 11, 2026 | RBC Capital | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.64 ▼ -10.3% | $-0.73 — $-0.52 | -19% YoY | 12 |
| Next Q | $-0.67 ▼ -6.9% | $-0.77 — $-0.53 | -17% YoY | 12 |
| Current FY | $-2.66 ▼ -11.0% | $-3.11 — $-1.23 | -28% YoY | 13 |
| Next FY | $-2.78 ▼ -41.1% | $-3.68 — $-1.32 | -5% YoY | 12 |
Latest Reports
NEUTRAL
8-K
3/10
CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur
May 26, 2026
BULLISH
Press
6/10
CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at
May 15, 2026
MIXED
8-K
5/10
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's $0.45 loss, and tot
May 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $271.5M | — |
| FMR LLC | $178.5M | ADD |
| BANK OF AMERICA CORP | $49.4M | ADD |
| MORGAN STANLEY | $22.6M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $22.5M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 4, 2026 | Liu Brian | A | $0.00 |
| Jun 4, 2026 | POST LEONARD | M | $0.00 |
| Jun 4, 2026 | POST LEONARD | M | $600.00 |
| Jun 4, 2026 | POST LEONARD | SELL | $54.5K |
| Jun 4, 2026 | POST LEONARD | A | $0.00 |
6 institutional holders with $547.1M total value (13,177,974 shares) as of 2025-Q4. Top holders: VANGUARD, FMR, BANK. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 6,539,482 | $271.5M | 49.6% | — |
| 2 | FMR LLC | 4,298,173 | $178.5M | 32.6% | ADD +51.5% |
| 3 | BANK OF AMERICA CORP /DE/ | 1,190,053 | $49.4M | 9.0% | ADD +59.0% |
| 4 | MORGAN STANLEY | 545,019 | $22.6M | 4.1% | TRIM -65.6% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 542,695 | $22.5M | 4.1% | NEW |
| 6 | WELLS FARGO & COMPANY/MN | 62,552 | $2.6M | 0.5% | ADD +72.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 748,345 | 1,190,053 | +59.0% | $49.4M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 36,255 | 62,552 | +72.5% | $2.6M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,736,769 | 748,345 | -56.9% | $30.1M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 1,868,148 | 642,414 | -65.6% | $25.9M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 46,100 | 0 | -100.0% | $0.00 | 2025-Q3 |
| FMR LLC | ADD | 2,545,098 | 3,856,261 | +51.5% | $100.3M | 2025-Q2 |
| UBS Group AG | ADD | 1,704,718 | 2,229,245 | +30.8% | $58.0M | 2025-Q2 |
| MORGAN STANLEY | ADD | 945,081 | 1,868,148 | +97.7% | $48.6M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 340,599 | 1,736,769 | +409.9% | $45.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 46,100 | — | $1.2M | 2025-Q2 |
| UBS Group AG | ADD | 1,013,891 | 1,704,718 | +68.1% | $41.7M | 2025-Q1 |
| MORGAN STANLEY | ADD | 725,227 | 945,081 | +30.3% | $23.1M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 341,563 | 1,218,953 | +256.9% | $35.0M | 2024-Q4 |
| UBS Group AG | DOUBLED | 86,534 | 1,013,891 | +1071.7% | $29.1M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 234,871 | 725,227 | +208.8% | $20.8M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 19,431 | 28,234 | +45.3% | $809.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 379,664 | — | $14.3M | 2024-Q3 |
| MORGAN STANLEY | DOUBLED | 94,709 | 234,871 | +148.0% | $8.9M | 2024-Q3 |
11 unique insiders with 3 transactions. Net insider value: -$1.2M ($0.00 bought, $1.2M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Liu Brian Guan-Chyun | Director | A | 9,354 | $0.00 | $0.00 |
| Jun 4, 2026 | POST LEONARD E | Director | M | 1,000 | $0.00 | $0.00 |
| Jun 4, 2026 | POST LEONARD E | Director | M | 1,000 | $0.6000 | $600.00 |
| Jun 4, 2026 | POST LEONARD E | Director | SELL | 1,000 | $54.50 | $54.5K |
| Jun 4, 2026 | POST LEONARD E | Director | A | 9,354 | $0.00 | $0.00 |
| Jun 4, 2026 | Mulay James | Director | A | 9,354 | $0.00 | $0.00 |
| Jun 4, 2026 | Graf Susan E | Director | A | 9,354 | $0.00 | $0.00 |
| Jun 4, 2026 | Rossi Christina | Director | A | 9,354 | $0.00 | $0.00 |
| Jun 4, 2026 | Tong Victor Edward Jr | Director | A | 9,354 | $0.00 | $0.00 |
| Apr 17, 2026 | Mulay James | Director | M | 15,600 | $36.63 | $571.4K |
| Apr 17, 2026 | Mulay James | Director | SELL | 15,600 | $73.01 | $1.1M |
| Apr 17, 2026 | Mulay James | Director | M | 15,600 | $0.00 | $0.00 |
| Apr 15, 2026 | Kuan Arthur | Chief Executive Officer | A | 271,600 | $0.00 | $0.00 |
| Apr 15, 2026 | DETORE JAMES M. | Chief Financial Officer | A | 90,574 | $0.00 | $0.00 |
| Apr 15, 2026 | Kasturi Vijay | Chief Medical Officer | A | 79,216 | $0.00 | $0.00 |
| Apr 15, 2026 | Patterson Joshua F. | See Remarks | A | 45,266 | $0.00 | $0.00 |
| Apr 15, 2026 | Bellete Ambaw | President and COO | A | 107,508 | $0.00 | $0.00 |
| Mar 16, 2026 | Mulay James | Director | SELL | 654 | $63.50 | $41.5K |
| Mar 16, 2026 | Mulay James | Director | M | 654 | $3.72 | $2.4K |
| Mar 16, 2026 | Mulay James | Director | M | 654 | $0.00 | $0.00 |
| Mar 12, 2026 | Kuan Arthur | Chief Executive Officer | F | 1,847 | $60.15 | $111.1K |
| Mar 12, 2026 | Kuan Arthur | Chief Executive Officer | M | 64,612 | $1.72 | $111.1K |
| Mar 12, 2026 | Kuan Arthur | Chief Executive Officer | M | 64,612 | $0.00 | $0.00 |
| Mar 4, 2026 | Kuan Arthur | Chief Executive Officer | M | 102,871 | $1.72 | $176.9K |
| Mar 4, 2026 | Kuan Arthur | Chief Executive Officer | M | 102,871 | $0.00 | $0.00 |
7 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 5 neutral. Avg impact: 4.0/10.
NEUTRAL
8-K
3/10
CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and a
May 26, 2026
MIXED
8-K
5/10
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, wider than the prior year's
May 8, 2026
NEUTRAL
PRESS-RELEASE
5/10
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.
May 8, 2026
NEUTRAL
DEFA14A
3/10
CG Oncology filed a definitive proxy statement (DEFA14A) for its upcoming shareholder meeting. This
Apr 24, 2026
NEUTRAL
144
3/10
James Mule, a director at CG Oncology, filed a Form 144 to notify intent to sell up to 17,564 shares
Apr 17, 2026
NEUTRAL
8-K
3/10
CG Oncology appointed Jim DeTore as Chief Financial Officer, effective April 13, 2026. The appointme
Apr 13, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 5 strong buy, 15 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$90.29 mean target
+59.3% upside
Strong Buy (3.00)
$80.00 Low
$108.00 High
| Metric | Value |
|---|---|
| Current Price | $56.67 |
| Target Low | $80.00 |
| Target Mean | $90.29 |
| Target Median | $88.50 |
| Target High | $108.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.64 | $-0.73 | $-0.52 | -18.8% | -10.3% | 3↑ 6↓ | $0.0B | 0.0% | 12 |
| Next Q 2026-09-30 |
$-0.67 | $-0.77 | $-0.53 | -17.1% | -6.9% | 3↑ 6↓ | $0.0B | -22.6% | 12 |
| Current FY 2026-12-31 |
$-2.66 | $-3.11 | $-1.23 | -27.7% | -11.0% | 2↑ 8↓ | $0.0B | 190.4% | 13 |
| Next FY 2027-12-31 |
$-2.78 | $-3.68 | $-1.32 | -4.7% | -41.1% | 0↑ 10↓ | $0.1B | 670.5% | 12 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.642 | |
| 7d ago | $-0.647 | +0.005 |
| 30d ago | $-0.582 | -0.060 |
| 60d ago | $-0.589 | -0.052 |
| 90d ago | $-0.678 | +0.037 |
7 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | Wolfe Research | INITIATE | — | Peer Perform |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 14, 2026 | Truist Securities | REITERATE | Buy | Buy |
| May 11, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| May 11, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| May 11, 2026 | Truist Securities | REITERATE | Buy | Buy |
| May 11, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Apr 27, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Apr 17, 2026 | JP Morgan | MAINTAIN | Overweight | Overweight |
| Apr 7, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 10, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 16, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 12, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 15 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 5 | 15 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 9, 2026
short_volume
Short Volume: CGON — 64.6% short (0.4M / 0.6M)
Short: 417,438 | Exempt: 130 | TRF Vol: 646,558 | Short Ratio: 64.6% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: CGON — 56.1% short (0.3M / 0.5M)
Short: 293,444 | Exempt: 152 | TRF Vol: 523,435 | Short Ratio: 56.1% | Off-exchange volume (dark pool + OTC)
May 28, 2026
other
CG Oncology to Present at Upcoming Investor Conferences in June
<p align="justify">DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President &
May 15, 2026
fda
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients
<p align="center"><em>- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Ev
May 11, 2026
earnings
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC
<p align="center"><em>-</em>First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed a
May 11, 2026
earnings_calendar
CGON Q1 2026 Earnings Scheduled — 2026-05-11
May 8, 2026
earnings
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
<p align="justify">DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the first quarter
May 7, 2026
earnings_calendar
CGON Q1 2026 Earnings Scheduled — 2026-05-07
Apr 8, 2026
short_volume
Short Volume: CGON — 60.6% short (0.3M / 0.6M)
Short: 343,225 | Exempt: 0 | TRF Vol: 566,655 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
Clinical Trial
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)
Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Sponsor: CG Oncology, Inc.
Phase: P
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)
Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Sponsor: CG Oncology, Inc.
Phase: P
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)
Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Sponsor: CG Oncology, Inc.
Phase: P
Mar 30, 2026
clinical_trial_readout
T-90d Trial Readout: Cretostimogene Grenadenorepvec (Phase 3)
Trial: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Sponsor: CG Oncology, Inc.
Phase: P
Mar 26, 2026
short_interest
FTD: CGON — 9,432 shares ($0.6M) failed to deliver
Settlement: 20260326, Price: $65.81, FTD Value: $620,719.92, CG ONCOLOGY INC COM
Mar 23, 2026
short_volume
Short Volume: CGON — 57.1% short (0.5M / 0.8M)
Short: 480,624 | Exempt: 17,373 | TRF Vol: 842,429 | Short Ratio: 57.1% | Off-exchange volume (dark pool + OTC)